Trial | NCT01494805  Report issue

Title

Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
A Phase I/II Controlled Dose-escalating Trial to Establish the Baseline Safety and Efficacy of a Single Subretinal Injection of rAAV.sFlt-1 Into Eyes of Patients With Exudative Age-related Macular Degeneration (AMD)

  • Phase

    Phase 1/Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    40
The study will involve approximately 40 subjects aged 55 or above who have exudative age-related macular degeneration (wet AMD). Patients will be randomized to receive one of two doses of rAAV.sFlt-1 or assigned to the control group.
A new treatment for exudative age-related macular degeneration (wet AMD) is being investigated. The purpose of this Phase I/II clinical research study is to examine the baseline safety and efficacy of an experimental study drug to treat a complication of the disease which leads to vision loss. The name of the study drug is rAAV.sFlt-1.

This experimental study uses a non-pathogenic virus to express a therapeutic protein within the eye. The therapeutic diminishes the growth of abnormal blood vessels under the retina. The duration of effect is thought to be long-term (years) following a single administration.

The clinical research study will look at the baseline safety and efficacy of a single injection of rAAV.sFlt-1 injected directly into the eye.

Approximately forty (40) subjects will participate in Australia. The primary endpoint of the study is at one month, with extended follow up for 3 years.
Study Started
Dec 31
2011
Primary Completion
May 31
2017
Study Completion
Aug 31
2017
Last Update
Sep 01
2017

Biological rAAV.sFlt-1

1 x 10^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection

Biological rAAV.sFlt-1

1 x 10^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection

Other Control (ranibizumab alone)

Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).

Low Dose rAAV.sFlt-1 Experimental

High Dose rAAV.sFlt-1 Experimental

Control - ranibizumab only Active Comparator

Criteria 

Inclusion Criteria:

Age greater than or equal to 55 years;
Subfoveal CNV secondary to AMD and with best corrected visual acuity of 3/60 - 6/9 with 6/60 or better in the other eye;
Fluorescein angiogram of the study eye must show evidence of a leaking subfoveal choroidal neovascular lesion, or CNV currently under active management with anti-VEGF therapy;
Must be a candidate for anti-VEGF intravitreal injections;
No previous retinal treatment of photodynamic therapy or laser;
Able to provide informed consent;
Able to comply with protocol requirements, including follow-up visits.

Exclusion Criteria:

Liver enzymes > 2 X upper limit of normal;
Any prior treatment for AMD in the study / control eye, excluding anti-VEGF injections;
Extensive sub-foveal scarring, extensive geographic atrophy, or thick subretinal blood in the study eye as determined by the investigator;
Significant retinal disease other than sub-foveal CNV AMD;
No Results Posted